The clinical activity of tyrosine kinase inhibitors (TKI) varies across cancer types of cancers bearing similar receptor tyrosine kinase (RTK) mutations. Analyzing public databases, we tested the ...
Oncogenic KRAS mutations are frequently detected in NSCLC. It remains a major challenge to target all KRAS mutants. MEK inhibitors are considered candidates for treating KRAS-mutant NSCLC; however, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results